BRIEF published on 08/20/2024 at 17:52, 3 months ago Terms of participation in the Medincell General Meeting Shareholders General Assembly Remote Voting Medincell Videoconference
PRESS RELEASE published on 08/20/2024 at 17:47, 3 months ago Terms of availability of the preparatory documents for the GM Medincell announces participation terms in the Combined General Meeting on September 12, 2024, including remote voting options, video conference for shareholders, and document availability Shareholders Combined General Meeting Remote Voting Medincell Participation Terms
BRIEF published on 06/28/2024 at 07:35, 4 months 23 days ago H.C. Wainwright & Co. Initiates MedinCell’s Coverage with "Buy" Recommendation FDA Approval BUY Rating Biopharmaceuticals H.C. Wainwright & Co. Medincell
PRESS RELEASE published on 06/28/2024 at 07:30, 4 months 23 days ago Inside Information / Other news releases H.C. Wainwright & Co. initiates coverage of MedinCell with a 'Buy' recommendation at €24 price target, reflecting +80% potential increase. MedinCell achieves milestones with FDA approvals, positive Phase 3 results, and collaboration with AbbVie FDA Approval Coverage Initiation H.C. Wainwright & Co. Medincell Pharmaceutical Sector
BRIEF published on 06/11/2024 at 09:05, 5 months 10 days ago Medincell Joins Euronext Tech Leaders Index Innovation Tech Sector Investor Visibility Medincell Euronext Tech Leaders
PRESS RELEASE published on 06/11/2024 at 09:00, 5 months 10 days ago Inside Information / Other news releases Medincell joins Euronext Tech Leaders, gaining access to a broad investor base and support services. CEO Christophe Douat highlights the company's growth and tech innovation leadership Tech Sector Financial Strategy Investor Base Medincell Euronext Tech Leaders
BRIEF published on 05/10/2024 at 18:05, 6 months 10 days ago Medincell announces details on capital and voting rights in accordance with regulations Euronext Paris Share Capital Voting Rights Financial Regulation Medincell
BRIEF published on 05/08/2024 at 12:35, 6 months 13 days ago Positive Results for the SOLARIS Phase 3 Trial of Olanzapine Schizophrenia Medincell SOLARIS Olanzapine TEV-'749
PRESS RELEASE published on 05/08/2024 at 12:30, 6 months 13 days ago Inside Information / Other news releases Teva and Medincell announce positive Phase 3 efficacy results from SOLARIS trial evaluating TEV-'749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia Schizophrenia Medincell Teva Phase 3 Efficacy Results SOLARIS Trial
BRIEF published on 05/08/2024 at 09:05, 6 months 13 days ago Medincell Temporarily Suspends its Euronext Paris Listing Euronext Paris Press Release Financial Markets Medincell Share Suspension
Published on 11/21/2024 at 13:00, 31 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 31 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 31 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 31 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 31 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 55 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 15 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 33 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 11 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 46 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 46 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
